Current investigative and clinical experience with alendronate in osteoporosis

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


The bisphosphonates represent a new class of pharmacologic agents that inhibit bone resorption and decrease the rate of bone turnover, making them of potential clinical value in the treatment of osteoporosis. Among these drugs, the new aminobisphosphonate alendronate (Fosamax(TM)) preferentially inhibits bone resorption at doses that do not inhibit mineralization, thus permitting continuous administration. In extensive clinical use, alendronate has been shown to reduce the turnover, and increase the density, of bone, and reduces the incidence of new vertebral fractures and loss of height in osteoporotic postmenopausal women.

Original languageEnglish (US)
Pages (from-to)103-118
Number of pages16
JournalToday's Therapeutic Trends
Issue number2
StatePublished - Jan 1 1996
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)


Dive into the research topics of 'Current investigative and clinical experience with alendronate in osteoporosis'. Together they form a unique fingerprint.

Cite this